{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015426","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.652328+00:00","generated_at":"2026-06-11T00:10:46.251422+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xilio Therapeutics appoints new President, CMO, CDO; Huber resigns to pursue CEO role","bullets":["Martin Huber, M.D., resigns as President and Head of R&D effective Sept 8; remains advisor.","CEO René Russo adds President title; previously served as President in 2021-2022.","Katarina Luptakova promoted to CMO; succeeds Huber with 20 years of oncology drug development experience.","Scott Coleman promoted to CDO; over 25 years in biotech, including at Acceleron and Merck.","Kevin Brennan enters employment agreement (base $370K, 35% bonus target) as SVP Finance."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015426","json":"https://secwatch.observer/filing/0001558370-23-015426.json","markdown":"https://secwatch.observer/filing/0001558370-23-015426.md","text":"https://secwatch.observer/filing/0001558370-23-015426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/xlo-20230830x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:10:46.251422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c538c9cf1","claim":"René Russo was appointed as President at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective September 8, 2023, the board of directors (the “Board”) of the Company appointed René Russo, Pharm.D., 48, to President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"ceca490d08","claim":"Martin Huber resigned as President and Head of Research and Development at Xilio Therapeutics, Inc..","evidence_excerpt":"Martin Huber, M.D., notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as President and Head of Research and Development of the Company, effective September 8, 2023, to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}